HeartSciences Posts $3.2M FQ1 Loss; Fortitude Merger on Track for Q4 Close
HSCS has more than doubled off its 52-week low of $1.63.
Summary
HeartSciences reported a $3.2M FQ1 2027 net loss and $2.0M shareholders' deficit, but raised $2.4M post-quarter without adjusting the Fortitude merger exchange ratio. First US commercial agreements for MyoVista Insights were signed, and the Fortitude merger is expected to close in Q4 2026.
Key Events · Earnings and Guidance · HSCS
-
FQ1 2027 Net Loss of $3.2M
Loss from operations widened to $2.9 million from $1.9 million a year ago, driven by $0.5 million in merger-related legal costs, $0.5 million in non-cash share-based compensation, and a $0.3 million inventory reserve.
-
$2.4M Raised Without Exchange Ratio Adjustment
Fortitude subscribed for $1.0 million of common stock in August 2026, the company raised $1.2 million net from ATM sales, and $200,000 of note principal converted to equity—none of which adjusted the merger exchange ratio, avoiding additional dilution for existing holders.
-
MyoVista Insights Commercial Traction
First US commercial agreements signed following full launch, and selection as the AI-ECG delivery platform for a clinical program at a major European reference center, anticipated to extend into a larger multicenter project.
-
wavECG Device Written Down
Company recorded a $0.3 million inventory reserve against the legacy MyoVista wavECG device and does not currently intend to commit significant additional resources to its commercialization, citing reduced commercial rationale from cloud-based AI-ECG algorithms.
Analysis · HSCS · Crypto Assets
A $3.2 million net loss and a $2.0 million shareholders' deficit marked HeartSciences' FQ1 2027, yet the company raised $2.4 million after quarter-end without adjusting the Fortitude merger exchange ratio—sparing existing holders from additional dilution. The quarter also brought the first US commercial agreements for MyoVista Insights and selection as the AI-ECG delivery platform for a major European reference center, while a $0.3 million inventory write-down signaled a retreat from the legacy wavECG device. The Fortitude merger remains on track for a Q4 2026 close, subject to shareholder approval.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HSCS was trading at $3.44 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $13.4M. The 52-week trading range was $1.63 to $4.35. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.